Details for Patent: 9,561,181

Title:	Crystal forms
Abstract:	The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.
Inventor(s):	Chen; Shuang (Gurnee, IL), Gates; Bradley D. (Mt. Prospect, IL), Sheikh; Ahmad Y. (Deerfield, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Apr 11, 2016
Application Number:	15/095,474
Claims:	1. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a solvent, thereby forming a solution, ##STR00002## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) as described in (a) any one of Tables 1a, 2a, 3a, and 4a or (b) any one of FIGS. 1-4. 2. The process of claim 1, wherein the solution further comprises an excipient. 3. The process of claim 1, wherein the solution further comprises a surfactant. 4. The process of claim 1, further comprising spray drying the solution, thereby forming a solid dispersion. 5. The process of claim 2, further comprising spray drying the solution, thereby forming a solid dispersion. 6. The process of claim 3, further comprising spray drying the solution, thereby forming a solid dispersion. 7. The process of claim 1, further comprising freeze drying the solution, thereby forming a solid dispersion. 8. The process of claim 2, further comprising freeze drying the solution, thereby forming a solid dispersion. 9. The process of claim 3, further comprising freeze drying the solution, thereby forming a solid dispersion. 10. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a solvent, thereby forming a solution, ##STR00003## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 11.1, 12.2, 14.5, 15, 15.9, 17.4, 17.8, and 22.2. 11. The method of claim 10, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 19.6, 19.9, 21.1, 22.2, 22.7, and 23.9. 12. The method of claim 11, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 6.7, 8.4, 8.9, 9.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 18.1, 18.9, 19, 19.6, 19.9, 21.1, 21.8, 22.2, 22.7, 22.8, 23.2, 23.9, 24.6, and 25.1. 13. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a molten hydrophilic polymer, thereby forming a melt, ##STR00004## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) as described in (a) any one of Tables 1a, 2a, 3a, and 4a or (b) any one of FIGS. 1-4. 14. The process of claim 13, wherein the melt further comprises an excipient. 15. The process of claim 13, wherein the melt further comprises a surfactant. 16. The process of claim 14, further comprising solidifying the melt, thereby forming a solid dispersion. 17. The process of claim 14, further comprising solidifying the melt, thereby forming a solid dispersion. 18. The process of claim 15, further comprising solidifying the melt, thereby forming a solid dispersion. 19. The process of claim 13, wherein the hydrophilic polymer is copovidone. 20. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a molten hydrophilic polymer, thereby forming a melt, ##STR00005## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 11.1, 12.2, 14.5, 15, 15.9, 17.4, 17.8, and 22.2. 21. The method of claim 20, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 19.6, 19.9, 21.1, 22.2, 22.7, and 23.9. 22. The method of claim 21, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 6.7, 8.4, 8.9, 9.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 18.1, 18.9, 19, 19.6, 19.9, 21.1, 21.8, 22.2, 22.7, 22.8, 23.2, 23.9, 24.6, and 25.1.